254 Results
Biodesix today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.”
Biodesix announced today that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
First Quarter 2022 Financial Results
Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods
Adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment
The Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, provides coverage for the Nodify CDT® lung nodule test.
Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.
Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9 in Chicago
Biodesix announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.
